Janssen-Cilag International NV Presents Long Term Phase III Efficacy And Safety Data Of Sirukumab In Rheumatoid Arthritis Patients Who Had An Inadequate Response And/Or Who Were Intolerant To Anti-TNFs Published: Jun 14, 2017 Email this Facebook Twitter LinkedIn Pinterest Reddit Back to news